Lilly cuts Zepbound vial prices and adds 7.5 mg and 10 mg doses

Eli Lilly cut the cash prices of its lowest-dose Zepbound vials and began selling two higher doses as single-dose vials for $499 a month on Feb. 25, 2025, the company said ^[3][5]. Zepbound's active ingredient is tirzepatide.

The 2.5 mg vial now costs $349 a month and the 5 mg vial $499, about $50 less per dose than before, Reuters reported ^[4]. Lilly confirmed those prices in its announcement ^[3][5]. The vials are sold only through LillyDirect Self Pay Pharmacy Solutions, outside insurance, and not through standard retail pharmacies ^[3][5].

The new 7.5 mg and 10 mg vials list at $599 and $699 a month. Under the new Zepbound Self Pay Journey Program, both cost $499 at a first fill and at refills that arrive within 45 days of the previous delivery ^[3][5]. A refill delivered later than that would cost $599 or $699, depending on the dose. Lilly's announcement does not describe a refill-timing condition for the 2.5 mg and 5 mg vials ^[3][5].

Zepbound is also sold in single-dose pens covering 2.5 mg through 15 mg, while the vials cover 2.5 mg, 5 mg, 7.5 mg and 10 mg ^[3][5]. The recommended maintenance doses are 5 mg, 10 mg or 15 mg once a week, and people starting the drug take 2.5 mg for four weeks before moving to 5 mg ^[3][5]. Lilly charges $650 for pens for patients who have insurance but whose plans do not cover the drug, which makes the $499 vial price nearly 23 percent lower, according to Reuters ^[4].

Reuters reported the move was aimed at competing with compounding pharmacies and Novo Nordisk ^[4]. The FDA removed Zepbound from its drug shortage list in December and removed Novo's Wegovy, a semaglutide product, on Feb. 21, 2025, telling compounders to stop selling copies in the coming months ^[4]. At that point, compounded versions sold for an average of $231 to $330 a month, Reuters reported ^[4]. Compounders led by the Outsourcing Facilities Association sued the FDA on Feb. 24 over the Wegovy and Ozempic decision, after an earlier lawsuit over tirzepatide ^[4].

"Every major medical organization and establishment recognizes obesity as a chronic disease, yet insurance and federal programs do not systematically cover people living with obesity for medical care — this needs to change," said Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA ^[3][5]. Joe Nadglowski, president and CEO of the Obesity Action Coalition, said the group applauds the step but that "we still have a long way to go in building a health care system that provides comprehensive care, coverage and payment" ^[3][5]. Jonsson told Reuters that more than 10 percent of patients starting Zepbound had started on vials since Lilly first offered them in August 2024 ^[4].

Why it matters for patients

People who pay cash rather than use insurance now have four Zepbound vial doses priced at $349 to $499 a month, instead of the two lower doses previously offered ^[3][5]. The 7.5 mg and 10 mg vials matter for people who move up in dose but stay on vials, since those are the two steps above the 5 mg starting strength ^[3][5]. The 12.5 mg and 15 mg strengths are not sold as vials, only as pens ^[3][5].

The 45-day refill window is new and applies to the 7.5 mg and 10 mg vials. Whether a delayed shipment, a dose change or a pause in treatment would reset the $499 price has not been reported. Lilly has not said how many patients use the higher-dose vials or how the 45-day rule will be tracked.

Compounded tirzepatide was cheaper than Lilly's vials at the time of the announcement, but regulators have moved to end those sales ^[4]. Whether compounded supply remains available, and for how long, depends on the FDA and ongoing litigation ^[4].

What happens next

Starting July 1, Novo Nordisk's Wegovy becomes the preferred GLP-1 for obesity treatment on CVS Caremark's largest commercial template formularies, and Zepbound will be excluded from plans using that standard list, a CVS spokesperson said ^[2]. People already taking Zepbound on those plans can switch to Wegovy or seek a medical exemption case by case, the spokesperson said ^[2]. Novo is also allowing CVS to sell Wegovy for $499 to cash-paying customers at more than 9,000 locations ^[2]. Lilly CEO David Ricks said he was "not surprised this kind of thing was announced" and that Lilly is "not interested at all in one-of-one deals of reducing access and choice for doctors and patients" ^[2].

Deadlines for compounding pharmacies to stop selling copies of tirzepatide and semaglutide depend on court decisions, and exact dates have not been disclosed ^[4].